公司董事会认为，公司本次回购股份事项符合《中华人民共和国公司法》《中 华人民共和国证券法》《关于支持上市公司回购股份的意见》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件及《公司 章程》的相关规定，审议该事项的董事会会议表决程序符合相关法律法规和《公 司章程》的相关规定。董事会同意公司使用超募资金以集中竞价交易方式回购公 司已发行的部分人民币普通股（A 股）股票。回购股份将在未来适宜时机全部用 于员工持股计划或股权激励计划，回购价格不超过 39.50 元/股，回购资金总额不 低于 3,000 万元，不超过人民币 5,000 万元；回购期限为自董事会审议通过本次 回购方案之日起 12 个月内。同时，为高效、有序、顺利地完成本次公司回购股 份工作，董事会授权公司管理层在法律法规规定的范围内办理本次回购股份的相 关事宜。 独立董事对上述事项发表了同意的独立意见。 证券代码：688246 证券简称：嘉和美康 公告编号：2023-045 表决结果：7 票同意，0 票反对，0 票弃权。 具体内容详见公司同日于上海证券交易所网站（http://www.sse.com.cn）披露 的《嘉 ...

3.回购股份的期限：自公司董事会审议通过回购方案之日起 12 个月内。 证券代码：688246 证券简称：嘉和美康 公告编号：2023-043 嘉和美康（北京）科技股份有限公司 关于收到公司控股股东、实际控制人、董事长提议 回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日收到公司控股股东、实际控制人、董事长夏军先生《关于提议嘉和美康（北京） 科技股份有限公司以集中竞价交易方式回购公司社会公众股股份的函》。提议内 容主要如下： 一、提议回购股份的原因和目的 夏军先生基于对公司未来发展的信心和对公司价值的认可，为建立完善公司 长效激励机制，充分调动公司员工的积极性，有效地将股东利益、公司利益和员 工利益紧密结合在一起，促进公司健康可持续发展，根据相关法律法规，夏军先 生提议公司以集中竞价交易方式回购部分社会公众股份。 二、提议内容 1.回购股份的种类及方式：通过上海证券交易所股票交易系统以集中竞价交 易方式回购公司已 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2023-042 嘉和美康（北京）科技股份有限公司持股 5%以上 股东减持股份计划提前终止暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，嘉和美康（北京）科技股份有限公司（以下简称"嘉 和美康"或"公司"）股东国寿成达（上海）健康产业股权投资中心（有限合伙） （以下简称"国寿成达"）持有公司股份 19,569,619 股，占减持计划披露时股份 总数的 14.19%。上述股份为嘉和美康首次公开发行并上市前取得的股份，且已 于 2022 年 12 月 14 日起上市流通。 减持计划的实施结果情况 公司于 2023 年 1 月 20 日披露了《嘉和美康持股 5%以上股东减持股份计划 公告》（公告编号：2023-005），国寿成达因自身资金需求，拟通过集中竞价方式 和大宗交易方式减持其持有的公司股份合计不超过 4,136,325 股，即不超过减持 计划披露时公司总股本的 3%。 公司于近日收到 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2023-030 嘉和美康（北京）科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 6 月 12 日(星期一) 至 6 月 16 日(星期五)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zqb@bjgoodwill.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年年度报告和 2023 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2022 年度和 2023 年第一季度经营成果、财务状况，公司计 划于 2023 年 6 月 19 日(星期一) 下午 15:00-16:00 举行 2022 年度暨 2023 年第 一季度业绩 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥107,504,828.76, representing a year-on-year increase of 9.67%[5]. - The net profit attributable to shareholders was a loss of ¥22,660,220.88, with a basic and diluted earnings per share of -¥0.16[5][6]. - The company reported a net loss of CNY 146,704,762.57, compared to a loss of CNY 124,044,541.69 in the previous period[17]. - Net loss for Q1 2023 was CNY 31,354,681.56, an improvement from a net loss of CNY 37,033,436.97 in Q1 2022, representing a 15.5% reduction in losses[19]. - Operating profit for Q1 2023 was CNY -40,240,317.00, compared to CNY -45,205,360.05 in Q1 2022, indicating a narrowing of the operating loss by 11.5%[19]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.16, an improvement from CNY -0.20 in Q1 2022[20]. Cash Flow - The net cash flow from operating activities was -¥147,248,515.51, indicating a significant cash outflow[6]. - The net cash flow from operating activities was -147,248,515.51, compared to -157,222,315.08 in the previous period, indicating a slight improvement[23]. - Total cash outflow from operating activities amounted to 262,132,612.30, down from 280,736,232.75 year-over-year[23]. - Cash inflow from operating activities totaled CNY 114,884,096.79, down from CNY 123,513,917.67 in Q1 2022, a decrease of 6.4%[21]. - Cash inflow from investment activities was 87,948.75, while cash outflow was 5,694,232.70, resulting in a net cash flow from investment activities of -5,606,283.95[23]. - Cash inflow from financing activities totaled 18,000,000.00, while cash outflow was 97,378,156.05, leading to a net cash flow from financing activities of -79,378,156.05[24]. - The net increase in cash and cash equivalents was -232,233,333.39, compared to -376,593,809.95 in the previous period[24]. - The ending balance of cash and cash equivalents was 461,002,187.62, down from 832,554,512.54 year-over-year[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,406,098,639.73, down 4.79% from the end of the previous year[6]. - As of March 31, 2023, the total assets of the company amounted to CNY 2,406,098,639.73, a decrease from CNY 2,527,045,461.81 as of December 31, 2022, representing a decline of approximately 4.8%[15]. - The company's current assets totaled CNY 2,114,696,359.84, down from CNY 2,260,656,635.23, indicating a decrease of about 6.5%[16]. - Total liabilities decreased to CNY 589,600,672.88 from CNY 683,425,530.94, a reduction of about 13.8%[17]. - The company's equity attributable to shareholders decreased to CNY 1,792,133,661.32 from CNY 1,810,796,740.66, reflecting a decline of approximately 1%[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,549[11]. - The largest shareholder, Xia Nian, holds 24,690,198 shares, representing 17.91% of the total shares[11]. Research and Development - Research and development expenses totaled ¥53,749,878.60, accounting for 50.00% of operating revenue, a decrease of 3.08 percentage points[6]. - Research and development expenses for Q1 2023 were CNY 44,689,485.21, down from CNY 48,010,998.55 in Q1 2022, a decrease of 6.9%[18]. Other Financial Metrics - The weighted average return on equity was -1.26%[6]. - The company reported non-recurring gains of ¥1,777,752.68 after tax adjustments[9]. - The company did not conduct an audit for the Q1 financial statements[4]. - The company reported a decrease in tax and additional charges from CNY 1,021,007.99 in Q1 2022 to CNY 628,194.19 in Q1 2023, a reduction of 38.5%[18]. - Other income for Q1 2023 was CNY 4,144,253.89, slightly down from CNY 4,127,492.69 in Q1 2022, indicating a marginal decrease of 0.4%[18]. - Payments to employees amounted to 124,081,671.31, compared to 162,704,726.52 in the previous period, reflecting a decrease[23]. - Payments for taxes were 15,032,583.30, slightly lower than 15,547,461.96 in the previous period[23]. - The company reported cash payments for other operating activities totaling 34,209,101.98, down from 48,755,694.02 year-over-year[23]. - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[24].

Financial Performance - The company reported a net loss of RMB 26,941,913.58 as of December 31, 2022, indicating that it does not meet the conditions for profit distribution in 2022 [6]. - The company has not declared any statutory surplus reserves or discretionary reserves for the year 2022 due to negative retained earnings [6]. - The company has not achieved profitability since its listing, as confirmed in the report [4]. - The company has not proposed any profit distribution plan for the reporting period due to the negative profit situation [6]. - The company's operating revenue for 2022 was CNY 716,948,756.64, representing a year-on-year increase of 9.97% compared to CNY 651,940,181.42 in 2021 [22]. - The net profit attributable to shareholders for 2022 was CNY 68,024,427.15, a significant increase of 37.13% from CNY 49,606,571.09 in 2021 [22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 53,829,864.75, a 37.00% increase from CNY 39,292,000.77 in 2021 [22]. - The net cash flow from operating activities decreased by CNY 61,729,038.95, primarily due to delayed customer payments and increased upfront investments in medical information projects [25]. - The weighted average return on equity decreased to 3.84% in 2022, down 6.73 percentage points from 10.57% in 2021 [23]. - The company reported a revenue of CNY 716.95 million for the year, representing a year-on-year increase of 9.97% [129]. - The operating cost for the year was CNY 350.57 million, which is a 10.21% increase compared to the previous year [129]. - The gross profit margin for the medical information industry was 51.12%, a decrease of 0.18 percentage points from the previous year [133]. Research and Development - Research and development expenses accounted for 24.71% of operating revenue in 2022, an increase of 5.47 percentage points from 19.24% in 2021 [23]. - The company achieved a total R&D investment of ¥177,152,231.62, representing a 41.24% increase compared to the previous year [90]. - The company applied for 18 new invention patents and received authorization for 8 during the reporting period, bringing the total number of authorized domestic invention patents to 28 [87][88]. - The company has developed 5 new core technologies that enhance medical data interoperability and utilization, bringing the total to 29 core technologies [82]. - The company’s R&D expenses increased by 26.60% to CNY 158.79 million, reflecting a significant investment in technology development [130]. - The number of R&D personnel is 687, accounting for 34.96% of the total workforce, with an average salary of $192,352.53, up from $122,312.27 in the previous period [107]. - Total compensation for R&D personnel increased to $132,146,190.77 from $84,640,092.32 in the previous period [107]. Market Position and Strategy - The company has maintained its position as the market leader in electronic medical record (EMR) systems in China for eight consecutive years, according to IDC data from 2014 to 2021 [72]. - The company has over 1,550 hospital clients, including more than 500 top-tier hospitals, representing over 25% of all top-tier hospitals in the country [72]. - The company ranks second in the Chinese medical big data solution market as of 2021, according to IDC [74]. - The company aims to become a leading player in the domestic medical informationization industry, focusing on clinical informationization and data application [170]. - The company plans to expand its product line by developing specialized electronic medical record systems and hospital data centers, addressing the pain points of large tertiary hospitals in data integration and utilization [173]. - The company has established a comprehensive customer acquisition and service network, achieving significant market share in its target market centered around tertiary hospitals [174]. Risks and Challenges - The company has detailed potential risks in the "Management Discussion and Analysis" section, emphasizing the importance of investor awareness regarding investment risks [7]. - The company faces risks related to changes in tax incentives, which could increase tax liabilities and negatively impact operating performance [124]. - The company is exposed to uncertainties in order acquisition and revenue growth due to varying levels of information technology needs among healthcare institutions [125]. - The company is at risk of increased bad debt losses due to rising accounts receivable and poor collection capabilities [122]. - The company is exposed to competitive risks in the medical informationization market, with increasing competition from new entrants [118]. Governance and Management - The company held its second extraordinary general meeting on July 15, 2022, where all proposed resolutions were approved without any rejections [181]. - The company plans to implement a stock option and restricted stock incentive plan for 2022, which was also approved in the second extraordinary general meeting [181]. - The company’s governance structure remains stable, with no significant changes reported in the red-chip structure [183]. - The company has established a remuneration assessment system for directors and senior management [199]. - The company has appointed several key personnel in management positions to strengthen its operational capabilities [192]. Future Outlook - The company expects a revenue guidance of 1.8 billion for the next fiscal year, indicating a growth target of 20% [188]. - The company plans to continue upgrading its intelligent comprehensive electronic medical record system and specialized electronic medical records to meet the long-term demand for intelligent, specialized, and customized solutions [173]. - Future efforts will focus on enhancing customer service efficiency and experience, increasing customer repurchase rates and value [174]. - The company will leverage policy support to penetrate and transform secondary hospitals and grassroots medical institutions, facilitating the implementation of hierarchical medical care reforms [174].

证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | |-----------------------|-------------------------------|---------------|----------------------------------------------------------------| | 投资者关系活动 \n类别 | □媒体采访 \n□现场参观 \n□其他 | | 特定对象调研 □分析师会议 \n□业绩说明会 \n□新闻发布会 □路演活动 | | | 华泰证券 | 范昳蕊 | | | | 嘉实基金 | 何鸣晓 | | | | 银河基金 | 沈怡 | | | | 新华资产 | 陈朝阳 | | | | 华商基金 | 刘力 | | | | 光大保德信基金 | | 安鹏 | | | 华泰柏瑞基金 | 杜聪 | | | 参与单位名称及 | 华泰柏瑞基金 | 陈碧野 | | | 人员姓名 | 国华人寿 | 安子超 | | | | 艾格基金 | Quinton ...

Financial Performance - Revenue for Q3 2022 reached ¥203,403,680.64, an increase of 16.77% year-over-year, while year-to-date revenue was ¥455,321,747.12, up 18.50%[5] - Net profit attributable to shareholders for Q3 2022 was ¥27,290,030.20, a significant increase of 497.42% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥26,480,915.84, up 482.19% year-over-year[5] - Basic and diluted earnings per share for Q3 2022 were both ¥0.20, a substantial increase of 348.07% compared to the same period last year[6] - The net profit for the third quarter of 2022 was a loss of ¥18,939,625.90, an improvement from a loss of ¥35,853,138.66 in the same quarter of 2021[24] - The total comprehensive income attributable to the parent company for Q3 2022 was 1,475,893.23 CNY, compared to a loss of 22,578,714.32 CNY in the same period last year[25] - The company reported a total comprehensive loss of -18,939,625.90 CNY for Q3 2022, compared to a loss of -35,853,138.66 CNY in the previous year[25] Research and Development - Research and development expenses totaled ¥45,293,137.80 for Q3 2022, representing 22.27% of revenue, an increase of 3.59 percentage points from the previous year[6] - The company plans to continue its focus on research and development, with increased investment in personnel and projects[12] - Research and development expenses increased significantly to ¥135,334,064.77 in the first three quarters of 2022, compared to ¥96,437,052.14 in 2021, marking an increase of 40.4%[23] - The company’s financial performance indicates a strategic focus on R&D and cost management, as evidenced by the increase in R&D expenses and the reduction in net losses compared to the previous year[24] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,333,501,121.18, a decrease of 4.56% compared to the end of the previous year[6] - The company reported a total asset value of ¥2,333,501,121.18 as of the end of the third quarter of 2022, down from ¥2,444,869,042.34 at the end of the previous year[20] - Total liabilities decreased to ¥550,007,469.04 in the third quarter of 2022, compared to ¥650,266,679.24 in the same quarter of 2021[19] - The total equity attributable to shareholders of the parent company was ¥1,744,263,095.29, slightly up from ¥1,734,956,287.12 in the previous year[20] - The company recorded a significant increase in inventory, which rose to ¥500,029,818.48 from ¥400,778,242.85 year-over-year, indicating a growth of 24.8%[20] Cash Flow - The company reported a cash flow from operating activities of -¥288,844,282.25 for the year-to-date period[6] - The net cash flow from operating activities for the first three quarters of 2022 was -288,844,282.25 CNY, worsening from -209,569,438.54 CNY in the previous year[27] - Cash inflow from operating activities totaled 401,685,600.36 CNY, while cash outflow amounted to 690,529,882.61 CNY, resulting in a net cash outflow of 288,844,282.25 CNY[27] - The company reported cash and cash equivalents at the end of Q3 2022 of 555,579,181.95 CNY, down from 1,109,148,322.49 CNY at the beginning of the period[28] - Investment activities generated a net cash flow of -107,819,577.63 CNY, compared to -1,337,468.54 CNY in the same period last year[28] - The company raised 28,578,000.00 CNY from borrowings in Q3 2022, a significant decrease from 167,608,589.00 CNY in the previous year[28] - The total cash outflow from financing activities was 185,486,225.29 CNY, compared to 83,406,534.89 CNY in the same period last year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,628[13] - The largest shareholder, Xia Jun, holds 24,690,198 shares, representing 17.91% of total shares[13] - The second-largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 19,569,619 shares, accounting for 14.19%[13] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 42%[14] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[15] Operational Insights - The report does not indicate any significant operational issues during the reporting period[16] - The company has not provided any future performance guidance or outlook in the current report[16] - There are no new product developments or market expansion strategies mentioned in the report[16]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders for the same period was RMB 20 million, up 10% compared to the previous year[19]. - The company's operating revenue for the first half of the year was approximately CNY 251.92 million, representing a 19.94% increase compared to CNY 210.04 million in the same period last year[21]. - The net loss attributable to shareholders was CNY 25.81 million, a slight improvement from a loss of CNY 27.15 million in the previous year[21]. - The basic earnings per share for the period was -CNY 0.19, compared to -CNY 0.26 in the same period last year[20]. - The company has set a revenue guidance of RMB 220 million for the full year 2022, indicating a growth target of 18%[19]. - The company achieved operating revenue of 251.92 million yuan, representing a year-on-year growth of 19.94%[81]. - The company reported a net loss of ¥-216,016,793.03, compared to a loss of ¥-190,202,656.06 in the previous period, indicating a worsening of approximately 13.6%[171]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, reflecting the company's commitment to innovation[19]. - Research and development expenses accounted for 40.97% of operating revenue, an increase of 10.55 percentage points from 30.42% in the previous year[20]. - Total R&D investment reached approximately ¥103.22 million, a year-on-year increase of 61.54%, with R&D expenses accounting for 40.97% of operating revenue, up from 30.42%[54][55]. - The number of employees engaged in research and development increased by 10.36% year-on-year, contributing to a significant rise in R&D spending[22]. - The company has a strong focus on original technology research and development in the healthcare information field, forming a proprietary technology and product system[48]. - The company has developed a core technology for medical big data that enhances data accuracy, consistency, and real-time responsiveness, achieving a leading level in the industry[50]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting tier-2 cities, expecting a 20% growth in user acquisition in these regions[19]. - The company plans to launch two new products in Q3 2022, aiming to capture an additional 5% market share in the healthcare sector[19]. - The company is exploring partnerships with international firms to enhance its technological capabilities and expand its product portfolio[19]. - The company is focused on expanding its market presence through new product development and technological advancements in healthcare information systems[60]. Product Development and Innovation - The company continues to focus on the development of medical information software, with a product portfolio that includes electronic medical record platforms and smart medical products[27]. - The electronic medical record platform has ranked first in the domestic niche market for eight consecutive years[30]. - The smart medical product system is driven by artificial intelligence and integrates real clinical data, covering multiple application scenarios such as clinical diagnosis and patient services[34]. - The company has developed an intelligent medical data platform that processes large-scale heterogeneous medical data, creating data models for various application scenarios[47]. Financial Position and Cash Flow - The net cash flow from operating activities decreased by CNY 120.70 million compared to the previous year, primarily due to pandemic-related disruptions and increased labor costs[22]. - The company's total assets decreased by 7.71% to CNY 2.26 billion from CNY 2.44 billion at the end of the previous year[21]. - The company reported a significant increase in prepayments, which rose by 47.09% to ¥125,418,796.97 from ¥85,264,869.40, reflecting the growth in business scale[105]. - The company reported a net cash outflow from operating activities of approximately -¥227.47 million, compared to -¥106.77 million in the previous year, indicating significant cash flow challenges[102]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[19]. - The company is exposed to macroeconomic risks, including potential impacts from natural disasters and pandemics, which could adversely affect its operations and revenue[100]. - The company faces uncertainties in order acquisition and revenue growth due to varying levels of information technology adoption among healthcare institutions, influenced by national policies[99]. Intellectual Property and Compliance - The company applied for 5 invention patents and received 5 invention patent authorizations during the reporting period, bringing the total number of domestic invention patents authorized to 25[53]. - The company holds 24 authorized invention patents and 748 software copyrights in the field of medical information technology[79]. - The company has not reported any violations or irregularities involving its directors, supervisors, senior management, or controlling shareholders during the reporting period[134]. Shareholder and Governance - The company has established measures to avoid competition with other enterprises controlled by its shareholders, ensuring compliance with fair market practices[132]. - The company emphasizes the importance of protecting investors' rights and has established a profit distribution policy, particularly regarding cash dividends, to ensure reasonable returns for investors[132]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period, reflecting good financial governance[133].

Financial Performance - The company reported a net loss of -38,792,427.91 RMB as of December 31, 2021, indicating that it does not meet the conditions for profit distribution in 2021[6]. - The company has not declared any statutory surplus reserves or discretionary reserves for the year 2021 due to negative retained earnings[6]. - The company has not proposed any profit distribution plan for the year 2021 due to the negative retained earnings situation[6]. - The company's operating revenue for 2021 was CNY 651,940,181.42, representing a year-on-year increase of 22.58% compared to CNY 531,837,003.60 in 2020[22]. - Net profit attributable to shareholders of the listed company reached CNY 49,636,904.83, a significant increase of 133.42% from CNY 21,265,425.26 in the previous year[22]. - The net cash flow from operating activities decreased by CNY 137,249,894.13, primarily due to the impact of the COVID-19 pandemic on client payment speeds and increased upfront investments in medical information projects[25]. - Total assets increased by 145.33% year-on-year to CNY 2,444,869,042.34, while net assets attributable to shareholders grew by 289.98% to CNY 1,734,956,287.12[25]. - The basic earnings per share for 2021 was CNY 0.48, up 128.57% from CNY 0.21 in 2020[23]. - The company reported a negative net cash flow from operating activities of -197.49 million yuan, primarily due to long project repayment cycles and high upfront costs[108]. - The company has cumulative undistributed losses of -38.79 million yuan in standalone reports and -190.20 million yuan in consolidated reports, affecting future profit distribution[109]. Governance and Compliance - The company has received a standard unqualified audit report from Dahua Certified Public Accountants[5]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[5]. - The company has not violated any decision-making procedures in providing guarantees to external parties[8]. - The company has not reported any special arrangements in corporate governance[9]. - The company has maintained a stable management structure with no significant changes in shareholding among key personnel during the reporting period[164]. - The company reported no changes in shareholding for independent directors and supervisors during the reporting period, with each receiving a pre-tax compensation of 6.00 million yuan[163]. - The company did not receive any penalties from securities regulatory agencies in the past three years[178]. Research and Development - The company invested 19.24% of its operating revenue in research and development, an increase of 1.89 percentage points from 17.35% in 2020[24]. - R&D investment totaled 125.43 million yuan, a year-on-year increase of 35.93%, with R&D personnel growing by 15.72%[33]. - The significant increase in R&D investment is attributed to the company's continued commitment to enhancing R&D efforts[78]. - The company applied for 40 invention patents during the reporting period and received 6 invention patent authorizations, bringing the total to 20 authorized invention patents by December 31, 2021[74]. - The company has developed 24 core technologies in the medical information field, with 21 of them applied to electronic medical records, hospital data centers, smart healthcare, and internet healthcare[70]. Market Position and Strategy - The company was recognized as a "Little Giant" enterprise by the state, reflecting its innovation and market position[31]. - The company has maintained its position as the market leader in electronic medical records (EMR) in China, ranking first for seven consecutive years from 2014 to 2020 according to IDC data[62]. - The company aims to become a leading player in the domestic medical information industry, focusing on clinical informationization and digital transformation[152]. - The company is focused on innovation, with core technical personnel involved in multiple technology-related firms, indicating a commitment to research and development[172]. - The company is exploring partnerships to leverage synergies in technology and market access[1]. Product Development and Innovation - The company launched several new products, including an integrated emergency platform and a VTE risk prevention system, enhancing its product offerings[36][37]. - The company has developed a comprehensive electronic medical record system for dental specialties, covering all current dental professional fields, enhancing daily diagnosis and treatment efficiency[48]. - The company is developing a one-stop research analysis platform to meet comprehensive research needs, including data retrieval and statistical analysis[154]. - The company has successfully launched multiple innovative product lines, including emergency and obstetric specialized electronic medical records, to meet the urgent demand for data integration and reuse[154]. Financial Health and Risks - The company faces risks from uncontracted project implementations, with costs of 71,000 yuan recognized without corresponding revenue due to inability to sign contracts[104]. - Inventory increased significantly, with a provision for inventory impairment of 14.62 million yuan, indicating potential risks if project contracts do not cover costs[109]. - The company is exposed to seasonal performance fluctuations, with significant revenue recognition occurring in the second half of the year, particularly in Q4[106]. - Changes in tax incentives could adversely affect the company's financial performance, as it currently benefits from reduced corporate income tax rates[110]. - The company is exposed to macroeconomic risks, including potential impacts from natural disasters and the resurgence of COVID-19, which could affect business operations[113]. Employee and Management Structure - The company has a total of 1,983 employees, with 54 in the parent company and 1,929 in major subsidiaries[186]. - The company has 692 R&D personnel, representing 34.90% of the total workforce, with an average salary of CNY 122,312.27[94]. - The overall compensation for the management team reflects a focus on retaining talent while ensuring stability in leadership roles[164]. - The company emphasizes a competitive and equitable salary structure, aligning with market conditions and employee performance[187]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 10% to 12%[168]. - The company plans to implement a new customer engagement strategy aimed at improving user retention by 15%[168]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[168]. - The company remains optimistic about future growth, driven by strong market demand and innovative product offerings[165].